Xi’an, China – March 20, 2024
Xi’an Springjia Bio-technique Co. Ltd, a leading biotechnology firm, has achieved a significant milestone in March by exporting tons of NMN (Nicotinamide Mononucleotide, CAS No: 1094-61-7). This accomplishment underscores the company’s strength and commitment to NMN projects as a focal point moving forward.
NMN, known for its potential health benefits and applications in various industries, has garnered increasing attention globally. Xi’an Springjia’s ability to export substantial quantities of NMN reflects its advanced manufacturing capabilities, quality assurance measures, and dedication to meeting global demand.
As a key player in the biotechnology sector, Xi’an Springjia continues to prioritize NMN projects, recognizing their importance in driving innovation and addressing health challenges worldwide. The company’s ongoing investment in research and development ensures the advancement of NMN-related technologies, positioning it as a frontrunner in the field.
Moving forward, Xi’an Springjia remains committed to further strengthening its NMN projects, delivering high-quality products, and contributing to advancements in health and biotechnology.